involvement of these ephrin members on the catabolic/anabolic activities of human OA chondrocytes. More specifically, we looked at the expression level and production of EphB4 receptor and ephrin B2, the activation of EphB4 receptor by ephrin B2 on the modulation of cartilage catabolic/anabolic mediators in the presence/absence of IL-1β, as well as the intra-cellular signaling pathways employed following EphB4 receptor activation. We further investigated factors that could modulate these ephrin members on OA chondrocytes. Methods: EphB4 receptor and ephrin B2 expression levels and modulation were analyzed by quantitative-PCR and their production by immunohistochemistry. The functional consequences of the ephrin B2-mediated EphB4 receptor activation were investigated by determining the production of some factors involved in the OA process, including IL-1β, IL-6, MMP-1, MMP-2, MMP-9, MMP-13, collagen type II and the receptor PAR-2. Results: The EphB4 receptor and ephrin B2 ligand are expressed by human normal and OA chondrocytes. Ephrin B2 is produced at similar levels and localized at the superficial zones in both normal and OA cartilage. In contrast, although in normal cartilage the EphB4 receptor is also only localized at the superficial zone, during OA it is observed throughout the cartilage layers with significant (p<0.01) increase in both the superficial and deep zones. This coincides with a significant increase in EphB4 receptor gene expression level in OA compared to normal (p<0.0001). Modulation experiments performed on OA chondrocytes showed that the receptor is inhibited by IL-1β and TNF-α. Interestingly, EphB4 activation significantly inhibited the gene expression levels of IL-1β, IL-6, MMP-1, MMP-9, MMP-13 and PAR-2, whereas MMP-2 was unaffected. It significantly increased collagen type II α1 expression and also inhibited the IL-1β-stimulated effect on the protein production of IL-6, MMP-1 and MMP-13. EphB4 receptor activation significantly reduced the PI3K/Akt pathway. Conclusions: Our study is the first to show the presence and role of ephrin B2/EphB4 receptor in human OA chondrocytes. The data support the notion that activation of the EphB4 receptor by ephrin B2 positively impacts the abnormal metabolism of OA cartilage by inhibiting important catabolic factors involved in this disease and at the same time as increasing the anabolic activity. Thus, ephrin B2 could act as a specific therapeutic approach in OA by acting both on cartilage and subchondral bone. Purpose: Osteoarthritis (OA) is the most common human joint disease. Recent studies suggest the involvement of osteoprotegerin (OPG), receptor activator of nuclear factor-κB (RANK) and RANK ligand (RANKL) in the abnormal OA subchondral bone metabolism; however, very few studies have looked at these factors in the articular chondrocytes or their functional consequences on these cells. We investigated the expression of OPG, RANK and RANKL on human chondrocytes comparing normal to OA, and the modulation of their production by some catabolic factors. Further, we evaluated on human OA chondrocytes the roles of OPG and RANKL on the production of catabolic/anabolic factors involved in this disease. Methods: Gene expression level was determined using real-time PCR. The protein production of RANK and RANKL were determined by flow cytometry, and that of OPG by a specific ELISA. Modulation of OPG, RANK and RANKL was determined upon treatment with IL-1β, TNF-α, and PGE 2 . The functional consequences were examined following treatment with either soluble RANKL or OPG-Fc (OPG without the heparin binding domain) at 50 and 100 ng/ml, and the production of catabolic factors including cytokines, MMPs and PAR-2, and the anabolic factor collagen type II evaluated. Results: OPG, RANK and RANKL were all expressed and produced by human chondrocytes. Interestingly, data showed that membranous RANK was produced only by an OA chondrocyte subpopulation (29%) which was localized throughout the cartilage. Compared to normal, the OPG/RANKL ratio was significantly (p=0.05) reduced on the OA chondrocytes, whereas the RANK/RANKL ratio was significantly (p<0.03) increased. Treatment with catabolic factors showed that OPG production and membranous RANKL levels were significantly enhanced by IL-1β, TNF-α, and PGE 2 , whereas membranous RANK was significantly increased only with IL-1β. Administration of soluble RANKL was without effect on the OA chondrocytes. However, addition of OPGFc significantly stimulated MMP-13 (p=0.05) and PAR-2 (p<0.04) production. Conclusions: Our findings showed that human normal and OA chondrocytes express and produce OPG, RANK, and RANKL. OA chondrocyte treatment with catabolic factors had variable effects on each member of the triad, but pointed to an increased biological effect of OPG. Interestingly, OPG, but not RANK or RANKL, appears to be involved in the progression of OA by significantly increasing two catabolic factors involved in cartilage pathophysiology, MMP-13 and PAR-2. Purpose: Pitx1 is an essential transcription factor for development and maintenance of bone and cartilage specifically in hindlimbs and mandible. Knockout of Pitx1 gene in mouse led to a sever abnormalities in morphogenesis of bone and cartilage tissues whereas Pitx1+/-mice progressively developed with ageing degenerative changes of the knee resembling human OA. These observations prompted us to investigate the role of this transcription factor in OA patients. We have discovered that Pitx1 mRNA and proteins were hardly expressed in human OA articular chondrocytes and cartilage sections when compared to matched control subjects. Recent results from our lab have also shown loss of Pitx1 expression in osteoarthritic (OA) chondrocytes. To understand the mechanism that leads to loss of Pitx1 expression in OA chondrocytes we have investigated the transcriptional regulation of this transcription factor in normal and OA chondrocytes. Methods: Human Pitx1 promoter gene was cloned upstream of a luciferase reporter gene. Using C28/I2 chondrocyte cell line, we have identified important regions for Pitx1 gene regulation using different complementary approaches (sequencing, mass spectrometry, DNA pull-downs method, ChIP assay and transient
MODULATION OF OSTEOPROTEGERIN, RANK, RANKL BY HUMAN CHONDROCYTES AND THEIR IMPLICATION IN OSTEOARTHRITIS
Purpose: Osteoarthritis (OA) is the most common human joint disease. Recent studies suggest the involvement of osteoprotegerin (OPG), receptor activator of nuclear factor-κB (RANK) and RANK ligand (RANKL) in the abnormal OA subchondral bone metabolism; however, very few studies have looked at these factors in the articular chondrocytes or their functional consequences on these cells. We investigated the expression of OPG, RANK and RANKL on human chondrocytes comparing normal to OA, and the modulation of their production by some catabolic factors. Further, we evaluated on human OA chondrocytes the roles of OPG and RANKL on the production of catabolic/anabolic factors involved in this disease. Methods: Gene expression level was determined using real-time PCR. The protein production of RANK and RANKL were determined by flow cytometry, and that of OPG by a specific ELISA. Modulation of OPG, RANK and RANKL was determined upon treatment with IL-1β, TNF-α, and PGE 2 . The functional consequences were examined following treatment with either soluble RANKL or OPG-Fc (OPG without the heparin binding domain) at 50 and 100 ng/ml, and the production of catabolic factors including cytokines, MMPs and PAR-2, and the anabolic factor collagen type II evaluated. Results: OPG, RANK and RANKL were all expressed and produced by human chondrocytes. Interestingly, data showed that membranous RANK was produced only by an OA chondrocyte subpopulation (29%) which was localized throughout the cartilage. Compared to normal, the OPG/RANKL ratio was significantly (p=0.05) reduced on the OA chondrocytes, whereas the RANK/RANKL ratio was significantly (p<0.03) increased. Treatment with catabolic factors showed that OPG production and membranous RANKL levels were significantly enhanced by IL-1β, TNF-α, and PGE 2 , whereas membranous RANK was significantly increased only with IL-1β. Administration of soluble RANKL was without effect on the OA chondrocytes. However, addition of OPGFc significantly stimulated MMP-13 (p=0.05) and PAR-2 (p<0.04) production. Conclusions: Our findings showed that human normal and OA chondrocytes express and produce OPG, RANK, and RANKL. OA chondrocyte treatment with catabolic factors had variable effects on each member of the triad, but pointed to an increased biological effect of OPG. Interestingly, OPG, but not RANK or RANKL, appears to be involved in the progression of OA by significantly increasing two catabolic factors involved in cartilage pathophysiology, MMP-13 and PAR-2. Purpose: Pitx1 is an essential transcription factor for development and maintenance of bone and cartilage specifically in hindlimbs and mandible. Knockout of Pitx1 gene in mouse led to a sever abnormalities in morphogenesis of bone and cartilage tissues whereas Pitx1+/-mice progressively developed with ageing degenerative changes of the knee resembling human OA. These observations prompted us to investigate the role of this transcription factor in OA patients. We have discovered that Pitx1 mRNA and proteins were hardly expressed in human OA articular chondrocytes and cartilage sections when compared to matched control subjects. Recent results from our lab have also shown loss of Pitx1 expression in osteoarthritic (OA) chondrocytes. To understand the mechanism that leads to loss of Pitx1 expression in OA chondrocytes we have investigated the transcriptional regulation of this transcription factor in normal and OA chondrocytes. Methods: Human Pitx1 promoter gene was cloned upstream of a luciferase reporter gene. Using C28/I2 chondrocyte cell line, we have identified important regions for Pitx1 gene regulation using different complementary approaches (sequencing, mass spectrometry, DNA pull-downs method, ChIP assay and transient transfections). These results were also validated using primary human OA chondrocytes. Results: Sequencing of a 10kb fragment upstream of human Pitx1 promoter allowed us to identify a SNP in a potential E2F respond element located in -3900/-3800 region of Pitx1 gene promoter. However, no association was found after validation of this SNP in a larger OA patient cohort (n=150). Nevertheless, using a 30bp probe, corresponding to the response element, and a DNA pull-down approach followed by mass spectrometry analysis (MS/MS), we discovered Prohibitin (PHB1) as the protein that interact with this response element. We confirmed this result with DNA pull-down followed by a Western blot against PHB1 and by chromatin immunoprecipitation (ChIP) assay. We have also found that in human OA chondrocytes, PHB1 is mostly accumulated in nucleus whereas in control subject it is mostly localized in cytoplasm. Overexpression of PHB1 in chondrocytes clearly demonstrated that PHB1 represses Pitx1 at mRNA and protein level. We also confirmed this repression using a gene reporter approach and point out that PHB1 use the -3900/-3800 response element discovered serendipitously. It has been shown that PHB1 represses the genes that are normally regulated by E2Fs transcription factor. Using a Luciferase reporter gene assay, we demonstrated that E2F1 is a transcriptional activator of Pitx1 gene and PHB1 over-expression block E2F1 effect on Pitx1 gene expression.
LOSS OF PITX1 TRANSCRIPTION FACTOR EXPRESSION IN OSTEOARTHRITIS OCCURS THROUGHT NUCLEAR

Conclusions:
In healthy subjects, Pitx1 is normally regulated by E2F1, but in OA condition, accumulation of PHB1 in chondrocyte nucleus leads to Pitx1 gene repression. Further work will be undertaken to determine the mechanism that lead to nuclear PHB1 accumulation in OA chondrocytes.
THE PROTECTIVE ROLE OF THE PERICELLULAR MATRIX IN CHONDROCYTE APOPTOSIS
H.C. Peters, Z. Zhang Saint Louis Univ., St. Louis, MO Purpose: In articular cartilage, pericellular matrix (PCM) plays a crucial role in homeostasis of chondrocytes. Apoptosis of chondrocytes contributes to common arthropathy such as osteoarthritis. This study attempted to quantify the protective role of the PCM in chondrocyte apoptosis using chondrons, which are a cartilage functional unit including a chondrocyte and its pericellular matrix. Methods: Chondrocytes and chondrons were enzymatically isolated from human articular cartilage and exposed to monoiodoacetate (MIA) and staurosporine for apoptosis induction. To identify chondrons, a basic component of the PCM, type VI collagen, was fluorescently labeled. Apoptosis of chondrocytes and chondrons was examined using flow cytometry and microscopy. Apoptosis and cell death were separately calculated in chondrons, the type VI collagen positive cell population, and chondrocytes. Results: Chondrocytes treated with MIA incurred a 26.97% increase in overall cell death compared to only 11.79% in chondrons. Chondrocytes treated with MIA underwent a 9.06% increase in apoptotic cells compared to only 1.64% in chondrons. Similarly, chondrocytes treated with staurosporine underwent a 13.64% increase in apoptotic cells while it was a 3.22% increase in chondrons. TUNEL staining revealed that apoptotic chondrocytes often were the core of cell aggregates, while apoptotic chondrons did not attract cell aggregation. Caspase3 was expressed in both stressed chondrocytes and chondrons. Conclusions: The PCM, a native microenvironment of chondrocytes, plays a protective role in chondrocyte survival. Retention of the PCM with chondrocytes is critically important in situations such as cartilage repair and tissue engineering, which depend on the survival of chondrocytes. Sulforaphane can inhibit tumourigenesis in animal models, has anti-inflammatory properties and of particular interest, is reported to inhibit histone deacetylase activity (Myzack et al; 2004) . Allicin, the pungent compound found in garlic, and related allyl sulfur compounds have been shown to inhibit the proliferation of several human tumour cell lines but not normal cells. These compounds have been shown to modify DNA methylation and acetylation (Lea et al; 2002) . Histone deacetylase inhibitors are potential chondroprotective agents (Young et al; 2005, Xu et al; 2006) . The aims of this project are to test the relative efficacy of dietary organosulfur compounds as HDAC inhibitors in human chondrocytes and to test the ability of such compounds to inhibit cartilage resorption in a bovine nasal cartilage explant model. Methods: Sulforaphane (SFN) and diallyl disulfide (DADS) were tested for their relative efficacy in modulating cytokine-induced metalloproteinase expression and histone acetylation in chondrocytes using quantitative RT-PCR and Western blotting. Furthermore, these compounds were tested for their ability to prevent cartilage destruction in the bovine nasal cartilage assay. Lactate dehydrogenase assays were used to test for toxicity. Results: Both SFN (5-10μM) and DADS (4-32μM) significantly attenuated IL-1β/oncostatin M-induced MMP1, MMP3, MMP13, and ADAMTS4 expression in SW1353 chondrosarcoma cells. MMP2 and MMP28 were not affected. Basal ADAMTS5 expression was repressed by SFN at 5-15μM. Global and histone H3 acetylation was not affected by SFN or DADS treatment in the SW1353 cell line. Cytokine-induced cartilage destruction was abrogated in a dose dependent manner by SFN (5-30μM) and DADS (8-32μM), measured by collagen and glycosaminoglycan release. Conclusions: Type II collagen and aggrecan are major structural components of cartilage. MMP-1 and MMP-13 are key collagenolytic metalloproteinases in arthritic disease since they can degrade collagen type II. ADAMTS-4 and ADAMTS-5 have aggrecanase activity. SFN and DADS can attenuate the induction of these genes in a dose dependent manner but do not appear to function through the inhibition of histone deacetylases. SFN and DADS are potential chondroprotective agents.
PHOSPHATE AND CALCIUM INFLUX ARE REQUIRED FOR TGFβ-MEDIATED STIMULATION OF ANK (progressive ankylosis) EXPRESSION AND PPi TRANSPORT FUNCTION DURING CHONDROGENESIS
P. Oca, R. Zaka, A.S. Dion, C.J. Williams Thomas Jefferson Univ., Philadelphia, PA Purpose: Genetic studies of familial chondrocalcinosis and cranial metaphyseal dysplasia have identified ANK, a multipass transmembrane protein, as a key player in biomineralization. The expression of ANK is stimulated by treatment of a variety of cell types with growth factors, including TGFβ. The purpose of this study was to determine whether TGFβ stimulation of ANK expression and function during chondrogenesis was dependent upon the influx of calcium and phosphate into the cells. Methods: ATDC5 cells were differentiated from immaturity through hypertrophy with and without the addition of TGFβ1. Inhibitors of TGFβ signaling were used to identify the signaling pathway em-
